Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026
Source: SeekingAlpha
2025-05-13 14:29:50 ET
More on Humacyte, Humacyte, Inc. WT EXP, etc.
- Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
- Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
- Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel
- Humacyte GAAP EPS of $0.28 beats by $0.47, revenue of $0.52M misses by $0.24M
- Humacyte Q1 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026
Humacyte Inc. Warrant
NASDAQ: HUMAW
HUMAW Trading
-26.0% G/L:
$0.0888 Last:
10,614 Volume:
$0.0969 Open:
HUMAW Latest News
HUMAW Stock Data
$247,325,345
156,832,240
N/A
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
